Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease

Nasopharyngeal carcinoma (NPC) is a non-lymphomatous squamous cell carcinoma that develops in the epithelial cells layer covering the surface of the nasopharynx. NPC is considered a diagnostic challenge to clinicians due to the difficulty in nasopharynx examination, and non-specific symptoms. The Ep...

Full description

Bibliographic Details
Main Author: Abusalah, Mai Abdel Haleem A.
Format: Thesis
Language:English
Published: 2021
Subjects:
Online Access:http://eprints.usm.my/50421/
http://eprints.usm.my/50421/1/MAI%20ABDEL%20HALEEM%20A.%20ABUSALAH-FINAL%20THESIS%20P-UD001017%28R%29%20-24%20PAGES.pdf
_version_ 1848881716483063808
author Abusalah, Mai Abdel Haleem A.
author_facet Abusalah, Mai Abdel Haleem A.
author_sort Abusalah, Mai Abdel Haleem A.
building USM Institutional Repository
collection Online Access
description Nasopharyngeal carcinoma (NPC) is a non-lymphomatous squamous cell carcinoma that develops in the epithelial cells layer covering the surface of the nasopharynx. NPC is considered a diagnostic challenge to clinicians due to the difficulty in nasopharynx examination, and non-specific symptoms. The Epstein–Barr virus (EBV) is well-associated with NPC. In addition, EBV LMP1 30 bp deletion was shown to play a vital role in enhanced oncogenic behaviour of EBV infected cells and results in more aggressive EBV-related tumour phenotypes. Therefore, this study intended to develop an innovative Taqman hydrolysis probe-based qPCR to detect the EBV's LMP1 30 bp deletion using whole blood samples from NPC patients. This developed assay will help the clinicians in early diagnosis, treatment response prediction, understand the extent of treatment effectiveness, and follow-up monitoring of NPC patients after treatment. In this developed i-qPCR, the mutant-specific primers, probes and multi-points degenerative blocker were designed. The Taqman hydrolysis probe-based qPCR parameters to detect the EBV's LMP1 30 bp deletion were also optimised. Internal control (IAC) was incorporated to rule out the false negative result. The demographic data of NPC patients were collected and used in the statistical analysis of this study. The assay validation was accomplished based on MIQE guidelines. The developed assay's analytical sensitivity was performed using 10-fold serial dilutions of MT gBLOCK (synthetic DNA). The analytical specificity was evaluated using 48 bacterial, fungal and virus genomic DNA and 12 extracted genomic DNA from archived biopsy tissue and fine-needle aspiration samples of NPC patients. The diagnostic evaluation of the developed assay was performed on 109 prospective specimens from NPC patients, non-NPC cancer patients and healthy individuals. The LOD of this developed assay was 173 copies/assay. The diagnostic evaluation showed 100% specificity, 83.3% sensitivity, 100% PPV and 98.7% NPV. A significant association was found between clinician treatment response prediction and Cq values of 30 bp deletion in this study (P-value= 0.033). In conclusion, this study was effective in developing an i-qPCR assay for early detection of 30 bp deletion tumour marker with high specificity and sensitivity, to help clinicians in treatment response prediction, and determine treatment effectiveness among NPC patients.
first_indexed 2025-11-15T18:23:27Z
format Thesis
id usm-50421
institution Universiti Sains Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T18:23:27Z
publishDate 2021
recordtype eprints
repository_type Digital Repository
spelling usm-504212021-10-28T04:14:36Z http://eprints.usm.my/50421/ Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease Abusalah, Mai Abdel Haleem A. R Medicine Nasopharyngeal carcinoma (NPC) is a non-lymphomatous squamous cell carcinoma that develops in the epithelial cells layer covering the surface of the nasopharynx. NPC is considered a diagnostic challenge to clinicians due to the difficulty in nasopharynx examination, and non-specific symptoms. The Epstein–Barr virus (EBV) is well-associated with NPC. In addition, EBV LMP1 30 bp deletion was shown to play a vital role in enhanced oncogenic behaviour of EBV infected cells and results in more aggressive EBV-related tumour phenotypes. Therefore, this study intended to develop an innovative Taqman hydrolysis probe-based qPCR to detect the EBV's LMP1 30 bp deletion using whole blood samples from NPC patients. This developed assay will help the clinicians in early diagnosis, treatment response prediction, understand the extent of treatment effectiveness, and follow-up monitoring of NPC patients after treatment. In this developed i-qPCR, the mutant-specific primers, probes and multi-points degenerative blocker were designed. The Taqman hydrolysis probe-based qPCR parameters to detect the EBV's LMP1 30 bp deletion were also optimised. Internal control (IAC) was incorporated to rule out the false negative result. The demographic data of NPC patients were collected and used in the statistical analysis of this study. The assay validation was accomplished based on MIQE guidelines. The developed assay's analytical sensitivity was performed using 10-fold serial dilutions of MT gBLOCK (synthetic DNA). The analytical specificity was evaluated using 48 bacterial, fungal and virus genomic DNA and 12 extracted genomic DNA from archived biopsy tissue and fine-needle aspiration samples of NPC patients. The diagnostic evaluation of the developed assay was performed on 109 prospective specimens from NPC patients, non-NPC cancer patients and healthy individuals. The LOD of this developed assay was 173 copies/assay. The diagnostic evaluation showed 100% specificity, 83.3% sensitivity, 100% PPV and 98.7% NPV. A significant association was found between clinician treatment response prediction and Cq values of 30 bp deletion in this study (P-value= 0.033). In conclusion, this study was effective in developing an i-qPCR assay for early detection of 30 bp deletion tumour marker with high specificity and sensitivity, to help clinicians in treatment response prediction, and determine treatment effectiveness among NPC patients. 2021-07 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/50421/1/MAI%20ABDEL%20HALEEM%20A.%20ABUSALAH-FINAL%20THESIS%20P-UD001017%28R%29%20-24%20PAGES.pdf Abusalah, Mai Abdel Haleem A. (2021) Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease. PhD thesis, Universiti Sains Malaysia.
spellingShingle R Medicine
Abusalah, Mai Abdel Haleem A.
Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title_full Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title_fullStr Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title_full_unstemmed Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title_short Development of real-time PCR assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (NPC) disease
title_sort development of real-time pcr assay for the early diagnosis, treatment response prediction and monitoring of nasopharyngeal carcinoma (npc) disease
topic R Medicine
url http://eprints.usm.my/50421/
http://eprints.usm.my/50421/1/MAI%20ABDEL%20HALEEM%20A.%20ABUSALAH-FINAL%20THESIS%20P-UD001017%28R%29%20-24%20PAGES.pdf